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Abstract
Background: The role of antibiotics in surgical procedures where the risk of surgical site infection (SSI) is low
remains uncertain. There is, to date, no evidence to justify the routine use of antibiotics in postoperative reduction
mammaplasty. The aim of this study is to evaluate the effect of postoperative antibiotic treatment on the
occurrence of SSI after breast reduction surgery.
Methods: This is a double-blind randomized clinical trial with 124 breast hypertrophy patients allocated to two
treatment groups: antibiotic (n = 62) and placebo (n= 62). All patients will undergo reduction mammoplasty, performed
by the same surgical team. The surgeons will raise the nipple-areola complex by the superomedial pedicle technique. The
patients will receive antibiotics intravenously during anesthetic induction and every 6 hours thereafter during their 24-
hour hospital stay. During discharge from the hospital, each patient will receive a numbered package containing either
cephalexin or placebo capsules and will be directed to take one capsule every 6 hours for 7 days. Neither the surgery
team nor the patients will know the contents of the capsules. Patients will be monitored for the occurrence of SSI once
weekly during the first 30 days following hospital discharge by a single surgeon who is blinded to their treatment group.
SSI will be evaluated based on the definition adopted by the Centers for Disease Control and Prevention.
Discussion: Due to the variety of risk factors for SSI and limited case studies, conclusions regarding the effect of
antibiotics on the occurrence of SSIs following reduction mammaplasty are potentially biased. In recent studies,
perioperative antibiotic prophylaxis was effective in preventing infection and is therefore recommended in clinical
practice. However, antibiotic use in the postoperative period still remains controversial.
Trial registration: Clinicaltrials.gov Identifier: NCT02569866. Registered on 4 October 2015.
Keywords: Plastic surgery, Mammaplasty, Wound infection, Prophylaxis
Background
Surgical site infections (SSIs) are defined as wound
infections that occur after invasive procedures and
remain among the most common infections, account-
ing for 14–16% of all nosocomial infections in hospi-
talized patients. In recent years, greater attention has
been paid to the study, prevention and control of
SSIs by surgeons, health care professionals, and
patients [1–4].
In a literature review of potential factors affecting the
occurrence of SSIs, Junker et al. noted that the timing of
antibiotic administration and the occurrence of surgical
glove perforation significantly influence the occurrence
of SSIs. Other factors, such as patient anemia, blood
transfusion during surgery, and surgeon experience were
not significant [3].
In many surgical procedures where the SSI risk is low,
the role of antibiotics remains uncertain. Despite the
lack of evidence of efficacy from randomized controlled
trials, its use in plastic surgery is widespread in order to
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offer patients greater presumed safety standards, because
even minor infections are able to interfere with the heal-
ing process and therefore the aesthetic result [4–11].
The prophylactic use of antibiotics was first studied by
Krizek et al., in 1975. These authors evaluated the pre-
scribing habits of surgeons over 10 years and demon-
strated an increased use of prophylaxis during this
period [3, 5, 12–15]. In a recent review article, Sajid
et al. concluded that prophylactic antibiotic therapy re-
duces the risk of SSI after breast surgery and the risk of
adverse reactions to this therapy was not significant [16].
SSIs related to breast surgeries occur at rates ranging
from 0.8 to 36%, which is the highest among clean sur-
geries as a whole (rate lower than 5%). This variation
can be attributed to the type of breast surgery per-
formed, patient comorbidities, duration of postoperative
follow-up, intraoperative complications and the availabil-
ity of institutional information [17–19]. Nevertheless,
there is, to date, no evidence to justify the routine
use of antibiotics in the postoperative of reduction
mammaplasty, and there is no consensus regarding its
prescription, even among surgeons of the same de-
partment [14, 20–22].
The Centers for Disease Control and Prevention
(CDC) define the specific criteria for the diagnosis of
SSIs as purulent drainage, positive aseptic culture, or
signs or symptoms of inflammation upon opening the
incision beyond superficial cellulitis [2, 19].
The impact of infection on wound healing after breast
reduction surgery ranges from minor complications,
such as marginal necrosis, which is common at the junc-
tion of the inverted “T” incision, to major infections that
require surgical intervention [23]. Many surgeons prefer
to administer antibiotics, believing that it will reduce the
incidence of these problems; however, previous studies
suggest that antibiotic prophylaxis fails to reduce the
rates of infection in clean surgeries, such as breast re-
duction [7, 14, 23–26].
Among studies conducted in different countries (United
Kingdom, Ireland, Israel, and the United States), there was
a tendency to prescribe prophylactic antibiotics beyond
the intra- and postoperative periods (24 hours) of breast
reduction, ranging up to 14 days. Cephalosporins were the
most frequently prescribed, with the exception of the UK,
which mentioned the use of amoxicillin/clavulanic acid in
70% of cases [9, 19, 21–23, 27–31].
Veiga-Filho et al. [32] compared SSI rates in patients
receiving cephalexin for 7 days after hospital discharge
(24 hours after breast reduction surgery) to patients who
did not receive antibiotics. They observed significantly
higher SSI incidence rates in the control group com-
pared with the experimental group receiving antibiotics
(14% vs. 2%, respectively; p = 0.03). They also observed
that the incidence of SSIs was greater in older patients
and in patients with a greater resected breast tissue mass
(p = 0.02; p = 0.04, respectively) [32].
Reduction mammaplasty is an effective procedure that
improves the quality of life for women with breast
hypertrophy and is one of the most common plastic sur-
gery procedures [33–36]. Prevention of SSIs is extremely
important, because infection may compromise the out-
come of the procedure, and increase the length of stay
and costs of hospitalization [37].
This study was designed to address the lack of consen-
sus on the role of antibiotics in breast reduction surgery.
Despite the absence of solid evidence, the use of antibi-
otics following reduction mammaplasty is widespread,
and a previous nonrandomized trial demonstrated
higher SSI rates when no antibiotics were used. Thus,
this trial was designed to compare the effectiveness of
antibiotics prophylaxis for 24 hours with the extended
use of antibiotics for 7 additional days.
The objective of this study is to evaluate the effect of
postoperative antibiotic treatment on SSI prevention in
breast reduction with perioperative prophylaxis.
Methods/Design
This is a randomized clinical trial with two parallel,
double-blind groups.
Study setting
This single-center study is being conducted in the
Academical Hospital of the Universidade do Vale do
Sapucaí. The hospital is located in the urban area of
Pouso Alegre, Minas Gerais, Brazil.
Eligibility criteria
Patients who meet the eligibility criteria and provide
their consent by signing an informed consent form are
eligible to join the study.
Inclusion criteria
Female patients are included in this study if they are be-
tween 18 and 60 years of age, have a body mass index
(BMI) between 19 and 30 kg/m2 and have breast hyper-
trophy according to the criteria of Sacchini et al. [38]
and Franco and Rebello [39].
Exclusion criteria
Patients are excluded if they had previously undergone
another surgical procedure of the breast, have been diag-
nosed with a breast pathology, are former smokers, have
had a child or breastfed within the last year, have uncon-
trolled comorbidities, such as arterial hypertension or
diabetes, or take immunosuppressants. Further, patients
who misuse capsules or miss follow-up assessments will
be excluded from analysis.
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Interventions
Surgical procedures
The patients will undergo reduction mammaplasty in the
surgical center of the hospital of the Universidade do Vale
do Sapucaí, by the same surgical team, lead by a single
surgeon. The superomedial pedicle technique will be used
to raise the nipple-areola complex [40].
All patients will be hospitalized the day before surgery
and will take a shower with a 4% chlorhexidine antiseptic
solution on the day of surgery [41, 42]. The operation will
be performed under general anesthesia, and antisepsis of
the operative field will be carried out with a 0.5% chlor-
hexidine alcohol solution [41, 42]. All patients will receive
antibiotics intravenously during surgery and during their
hospital stay (cephalothin, 1 g at induction of anesthesia
and every 6 hours).
Outcome procedures
On the first postoperative day, prior to hospital discharge,
the assistant surgeon will remove the dressing from the in-
cision and will instruct the patient on how to wash the
wound daily with soap and water. Patients will also be
instructed to wear a postoperative bra (MaCom® - Malhas
de Compressão, Brazil - Ref 1002) for 30 days, and to avoid
driving and working out for the same period.
After 24 hours, at hospital discharge, the assistant sur-
geon will give the patient a package with her protocol
number, containing 28 capsules (cephalexin 500 g or
placebo 500 g), and instruct her to take one every 6 hours
for 7 days. Specially produced capsules containing either
the antibiotic or placebo were kindly provided by Cimed
Indústria de Medicamentos Ltda, São Paulo, Brrazil, who




Face-to-face reminder sessions as to the importance of
treatment adherence occur the day before surgery and at
each weekly postoperative appointment. Such sessions
include:
– Clear instructions are provided for all prescriptions
and, after asking whether the patient has any
questions, the patient is asked to repeat the
instructions in their own words.
– The confirmation about the correct use of the capsules
during the first 7 days of the postoperative period.
– The importance of following medical
recommendations on the use of the bra and surgical
wound care.
– The questioning of possible events that could
constitute exclusion criteria as described in
methods.
Outcome measures
The CDC considers an infection to be an SSI when it
appears to be related to the surgical procedure and pre-
sents within 30 days of the operation. If implants are
inserted during the surgery, the time frame is extended
up to a year after the surgery [1]. CDC classifies SSI into
three categories, superficial incisional, deep incisional or
organ/space SSI. In the present study, as none of the pa-
tients received an implant, requiring a delayed assess-
ment, patients will be monitored for the occurrence of
infection once a week for the first 30 days following
surgery as assessed by a single surgeon, who is a senior
plastic surgeon, with extensive experience in breast sur-
gery. This surgeon will diagnose the presence or absence
of SSI, thus dichotomizing the outcome as development
of SSI (Yes/No). In case of a SSI, it will be classified
according to CDC’s criteria, by the same surgeon [1].
Sample size
The experimental and control groups were designed for
62 patients each to ensure a significance level of 5% and
power of 80%. This was calculated based on the propor-
tions observed in a previous study with and without the
use of antibiotics after breast reduction [32].
Recruitment
The recruitment started in April 2012. The 124 breast
hypertrophy patients will be selected from the plastic
surgery clinics of the hospital of the Universidade do
Vale do Sapucaí, where these procedures are routinely
performed and followed, ensuring patient compliance.
All surgeries will be performed in the operating room of
this hospital.
Allocation – randomization
Patients will be randomly allocated into the study groups
based on a random sequence generated by Bioestat 5.0
software (Instituto Mamirauá, Belém, Brazil). Patients in
the experimental group (n = 62) will receive 500 mg
cephalexin capsules, while patients in the placebo group
(n = 62) will receive placebo capsules, that are identical
in appearance to the antibiotic capsules. The anti-
biotic and placebo capsules were provided in identical
packages containing the exact number of capsules for
each patient.
Allocation – concealment mechanism
A researcher, who will not participate in the care of
patients, numbered the packages from 1 to 124 as per
the randomly generated sequence. At the time of
hospital discharge, each patient will receive a serial num-
ber and the corresponding numbered package contain-
ing the capsules that she will take.
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Allocation – implementation
Only one of the researchers will have access to the ran-
dom sequence. He will not be responsible for recruiting
patients, performing surgical procedures, distributing
the packages, or performing postoperative follow-up, en-
suring allocation concealment.
Blinding
The surgery team, the assistant surgeon who instructs
patients regarding the capsule intake and the surgeon
who evaluates the SSIs are blinded to the allocation
group. In addition, the patients are not informed about
the contents of their prescribed capsules.
The first assessment regarding SSI is after 7 days.
However, patients are instructed to contact the assistant
surgeon in case of pain, fever or any other intercurrence
before this first assessment. If the assistant surgeon diag-
noses a SSI during the use of the antibiotic or placebo,
the appropriate antibiotic treatment is immediately
established and the use of the study capsules is sus-
pended, without unblinding. Table 1 presents the sched-
ule of the trial.
Data collection methods
Researchers will collect demographic data using a stan-
dardized form for each patient during their first medical
appointment. Data from weekly postoperative appoint-
ments evaluating SSIs will also be collected using a stan-
dardized form.
Data management
All data collected during the study will be entered into a
unique spreadsheet, respecting the allocation and blind-
ing. At the end of the study, after the last patient has
been recruited, operated on and completed follow-up,
the allocation group of each patient will be revealed and
separate spreadsheets will be prepared for the data from
experimental and placebo groups. The data from these
two spreadsheets will be then compared with each other.
Each patient will be identified only by a protocol num-
ber (the number of her package), to protect her privacy.
Statistical methods
Statistical methods – outcomes
The data will be entered into the statistical software
Bioestat, version 5.0 (Instituto Mamirauá, Belém, Brazil).
Descriptive statistics will be used to evaluate numerical
variables, with calculation of the median, mean and
standard deviation. The Mann-Whitney test will be used
to compare the groups in age, BMI, duration of surgery,
and weight of resected breast tissue.
The chi-square test or Fisher’s exact test will be used
to compare the occurrence of SSIs among the groups.
Those tests will be also used to study associations
between the occurrence of infection and age, BMI,
duration of the surgery, and weight of resected breast
tissue in each group. For these variables, the values for
each group will be divided into below the median and
above the median.
Statistical methods – analysis population and missing
data
Data analysis will be performed based on the original al-
location of all patients as defined by randomization, re-
gardless of the degree of adherence to the protocol
(intention-to-treat principle). With respect to missing
data, the amount thereof, their patterns and the variables
associated with omission will define the most appropri-
ate technique to be used in the processing of such data,
whether in the primary analysis or the sensitivity
Table 1 Schedule of enrolment, interventions, and assessments for “Antibiotic prophylaxis in reduction mammaplasty: a randomized
controlled trial”
Study period
Enrolment Allocation Post-allocation Close-out
Timepoint Apr/2012–Dec/2016 Jan/2015–Jan/2017 Jan/2015–Jan/2017 Feb/2015–Feb/2017 Mar/2017
Enrolment:
Eligibility screen X




[Antibiotic or placebo prescription] X X
Assessments:
[Eligibility criteria] X X
[SSI assessment ] - X X
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analysis. For primary analyses, methods will be used that
make use of all available data, such as multiple
imputations.
Monitoring
In addition to the weekly evaluation regarding SSI, all
the patients will be instructed to contact the assistant
surgeon if they have any issue related to the operation
or to the use of the capsules. In case of a diagnoses of
SSI or if any problem related to the use of the capsules
is recorded, the intake of the capsules will be immedi-
ately discontinued and the appropriate conduct will be
taken in each case.
Ethics and dissemination
The study protocol was approved by the institutional
ethics committee, and all the subjects signed an in-
formed consent form prior to enrollment.
Protocol amendments
Any modifications of the protocol that may impact the
study, the potential benefit to patients or patient safety,
including changes of the study objectives, study design,
patient population, sample size, study procedures or
other significant aspects will require a formal amend-
ment to the protocol. Such modification shall be agreed
upon between the researchers and approval will be ob-
tained from the Research Ethics Committee before
implementation.
Confidentiality
All participant information will be kept in password-
protected files with limited access. Data that identify the
participants will be replaced by codes.
Access to data
All researchers involved in the study will have access to
all data collected.
Dissemination policy – authorship
The criteria for authorship of this protocol followed the
guidelines established by the International Committee of
Medical Journal Editors. A team of professional translators
was used to translate the text from Portuguese into Eng-
lish. The final report will follow the main CONSORT
2010 guidelines.
Discussion
Breast reduction was the eleventh most performed cos-
metic procedure in the United States in 2014 (American
Society of Plastic Surgeons). It is classified as a “clean
operation”, although it has higher rates of infection than
other procedures in the same category [18].
Studies comparing factors that affect the occurrence of
SSIs in breast surgeries such as smoking, use of a surgical
drain, preoperative chemotherapy, breast reconstruction,
and associated administration of antibiotic prophylaxis,
have presented conflicting conclusions [17, 29, 37, 43–47].
In three SSI cohort studies the recruited patients had dif-
ferences in risk factors, preventing a quality meta-analysis
[17, 43, 48, 49]. Finally, most of the available studies are
related to the treatment of breast cancer and not specific-
ally to breast reduction, emphasizing the importance of
this study.
We chose to exclude women who have risk factors for
SSIs in an attempt to homogenize the sample, allowing us
to isolate the postoperative prophylaxis factor. In addition,
pre- and intraoperative care related to infection control
will be taken, including antiseptic treatment of the op-
erative field, routine antibiotic prophylaxis, hemostasis,
care and caution to detachments, handling and prepar-
ation of the flaps without tension sutures and sterile
dressing will be taken.
Short et al. [18] performed a meta-analysis on SSIs
from reduction mammaplasties, and found only three
randomized clinical trials. They concluded that pre-
operative antibiotic prophylaxis is effective in preventing
SSIs in reduction mammaplasties; they determined a de-
crease in the incidence of SSIs of 75%, compared with
placebo or no medication, and therefore recommended
its use in clinical practice. Their meta-analysis also
highlighted the importance of randomized controlled tri-
als to evaluate the postoperative prophylaxis, which has
yet to be done [18, 23, 29, 50].
As well as in other studies in which cephalosporins are
the main used antibiotics following reduction mamma-
plasties, we chose to use two different first-generation
cephalosporins: cephalothin, for intravenous use in the
intraoperative period and the first 24 hours (1 g each
6 hours) and cephalexin for oral use (500 g every
6 hours) in the subsequent postoperative 7 days, com-
pared to placebo [9, 19, 21–23, 27–31].
The objective of the current study is to evaluate the
role of antibiotic prophylaxis extended through the post-
operative 7 days, in patients who have intraoperative use
of cephalothin (every 6 hours, during the first 24 hours),
seeking to assess the impact of extended prevention in
the SSI rates.
Based on the evidence described and taking into ac-
count the study design, the results may justify standard
protocols for the use of antimicrobial prophylaxis in
breast reduction.
Trial status
This trial is in the recruiting stage. The first patient was
randomized in April 2012; by January 2016, a total of 90
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patients had undergone surgery, and none of the pa-
tients had any infection during the first 30 days.
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